SEC Form S-8 filed by Larimar Therapeutics Inc.
As filed with the United States Securities and Exchange Commission on March 24, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
LARIMAR THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 20-3857670 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
| Three Bala Plaza East, Suite 506 Bala Cynwyd, Pennsylvania |
19004 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Larimar Therapeutics, Inc. 2020 Equity Incentive Plan
(Full title of the plan)
Carole S. Ben-Maimon, M.D.
President and Chief Executive Officer
Larimar Therapeutics, Inc.
Three Bala Plaza East, Suite 506
Bala Cynwyd, Pennsylvania 19004
(Name and address of agent for service)
(844) 511-9056
(Telephone number, including area code, of agent for service)
Copies to:
Rachael M. Bushey, Esq.
Jennifer L. Porter, Esq.
Goodwin Procter LLP
3025 John F Kennedy Blvd
Philadelphia, PA 19104
(445) 207-7805
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
| Emerging growth company | ☐ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement is being filed for the purpose of registering an additional 2,552,603 shares of common stock, par value $0.001 per share (the “Common Stock”), of Larimar Therapeutics, Inc. (the “Registrant”) that were added to the shares authorized for issuance under the Larimar Therapeutics, Inc. 2020 Equity Incentive Plan (the “Plan”) as a result of the operation of an automatic annual increase provision included therein and for which a Registration Statement on Form S-8 relating to the same employee benefit plan is effective.
The Registrant previously filed Registration Statements on Form S-8 (File Nos. 333-249287, 333-270535 and 333-277946) with the Securities and Exchange Commission (the “Commission”) to register 6,510,258 shares of Common Stock that were authorized for issuance under the Plan. Upon the effectiveness of this Registration Statement, an aggregate of 9,062,861 shares of Common Stock will be registered for issuance from time to time under the Plan. Pursuant to General Instruction E to Form S-8, the contents of the Registration Statements on Form S-8 (File Nos. 333-249287, 333-270535 and 333-277946) filed with the Commission on October 2, 2020, March 14, 2023 and March 14, 2024 are incorporated herein by reference except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier registration statement are presented herein.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
| Item 3. | Incorporation of Documents by Reference. |
The following documents of the Registrant filed with the Commission are incorporated by reference in this Registration Statement as of their respective dates:
(a) the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 24, 2025;
(b) the Registrant’s Current Reports on Form 8-K (in each case other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports related to such items) filed with the Commission on January 10, 2025, January 27, 2025 and March 24, 2025; and
(c) the description of the Registrant’s Common Stock contained in the Registration Statement on Form 8-A filed with the Commission on June 18, 2014 (File No. 001-36510), together with any amendment thereto filed with the Commission for the purpose of updating such description.
All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (other than information furnished under Item 2.02 or 7.01 of Form 8-K and exhibits furnished on such form that relate to such items unless such form expressly provides to the contrary) prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents.
Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement.
| Item 8. | Exhibits. |
The following documents are filed as exhibits to this Registration Statement:
| * | Filed herewith |
| # | Denotes management contract or compensatory plan or arrangement. |
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Bala Cynwyd, Commonwealth of Pennsylvania, on March 24, 2025.
| LARIMAR THERAPEUTICS, INC. | ||
| By: | /s/ Carole S. Ben-Maimon, M.D. | |
| Carole S. Ben-Maimon, M.D. | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of Carole S. Ben-Maimon, M.D. and Michael Celano as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments thereto), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
| Signature |
Title |
Date | ||
| /s/ Carole S. Ben-Maimon, M.D. Carole S. Ben-Maimon, M.D. |
President, Chief Executive Officer and Director (Principal Executive Officer) |
March 24, 2025 | ||
| /s/ Michael Celano Michael Celano |
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
March 24, 2025 | ||
| /s/ Joseph Truitt Joseph Truitt |
Chairman, Board of Directors | March 24, 2025 | ||
| /s/ Thomas E. Hamilton Thomas E. Hamilton |
Director | March 24, 2025 | ||
| /s/ Jonathan Leff Jonathan Leff |
Director | March 24, 2025 | ||
| /s/ Jeffrey W. Sherman, M.D., FACP Jeffrey W. Sherman, M.D., FACP |
Director | March 24, 2025 | ||
| /s/ Frank Thomas Frank Thomas |
Director | March 24, 2025 | ||